192 related articles for article (PubMed ID: 30853214)
41. SWI/SNF component
Wang SC; Nassour I; Xiao S; Zhang S; Luo X; Lee J; Li L; Sun X; Nguyen LH; Chuang JC; Peng L; Daigle S; Shen J; Zhu H
Gut; 2019 Jul; 68(7):1259-1270. PubMed ID: 30315093
[TBL] [Abstract][Full Text] [Related]
42. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
43. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
44. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
[TBL] [Abstract][Full Text] [Related]
45. Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis.
Carrer A; Trefely S; Zhao S; Campbell SL; Norgard RJ; Schultz KC; Sidoli S; Parris JLD; Affronti HC; Sivanand S; Egolf S; Sela Y; Trizzino M; Gardini A; Garcia BA; Snyder NW; Stanger BZ; Wellen KE
Cancer Discov; 2019 Mar; 9(3):416-435. PubMed ID: 30626590
[TBL] [Abstract][Full Text] [Related]
46. Differential Cell Susceptibilities to Kras
Shi C; Pan FC; Kim JN; Washington MK; Padmanabhan C; Meyer CT; Kopp JL; Sander M; Gannon M; Beauchamp RD; Wright CV; Means AL
Cell Mol Gastroenterol Hepatol; 2019; 8(4):579-594. PubMed ID: 31310834
[TBL] [Abstract][Full Text] [Related]
47. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
48. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
[TBL] [Abstract][Full Text] [Related]
49. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.
Mayers JR; Torrence ME; Danai LV; Papagiannakopoulos T; Davidson SM; Bauer MR; Lau AN; Ji BW; Dixit PD; Hosios AM; Muir A; Chin CR; Freinkman E; Jacks T; Wolpin BM; Vitkup D; Vander Heiden MG
Science; 2016 Sep; 353(6304):1161-5. PubMed ID: 27609895
[TBL] [Abstract][Full Text] [Related]
50. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
51. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
52. Atypical flat lesions derive from pancreatic acinar cells.
von Figura G; Fahrenkrog-Petersen L; Hidalgo-Sastre A; Hartmann D; Hüser N; Schmid RM; Hebrok M; Roy N; Esposito I
Pancreatology; 2017; 17(3):350-353. PubMed ID: 28473229
[TBL] [Abstract][Full Text] [Related]
53. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
54. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
55. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
56. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
57. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
[TBL] [Abstract][Full Text] [Related]
58. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
59. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
[TBL] [Abstract][Full Text] [Related]
60. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]